News
EXEL
23.70
+0.70%
0.17
Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
NASDAQ · 10h ago
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
NASDAQ · 3d ago
Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors
Exelixis, Inc.'s (NASDAQ:EXEL) price-to-earnings ratio of 32x might make it look like a strong sell. The company has a high P/E compared to the market in the United States. Exelix is expected to grow earnings by 45% per year in the coming years. However, the company's P/e might be high for a reason and needs to be investigated.
Simply Wall St · 4d ago
Weekly Report: what happened at EXEL last week (0415-0419)?
Weekly Report · 4d ago
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
Exelixis, Inc. Will release its first quarter 2024 financial results on April 30, 2024 after the markets close. The company will host a conference call and webcast to discuss the results and provide a business update. The event will be available via the Internet from the company's website.
Barchart · 04/16 15:05
Weekly Report: what happened at EXEL last week (0408-0412)?
Weekly Report · 04/15 09:01
Exelixis slips as Barclays downgrades on lack of catalysts
Barclays downgrades cancer drugmaker Exelixis on lack of catalysts. Lead asset cabozantinib faces a patent cliff, analyst says. Barclays sees better upside potential in other companies with similar pipelines. Exelxis shares traded lower on Thursday.
Seeking Alpha · 04/11 14:10
Exelixis Price Target Maintained With a $25.00/Share by Barclays
Dow Jones · 04/11 13:05
Exelixis Cut to Equal-Weight From Overweight by Barclays
Dow Jones · 04/11 13:05
Barclays Downgrades Exelixis to Equal-Weight, Maintains Price Target to $25
Benzinga · 04/11 12:55
EXELIXIS INC <EXEL.O>: BARCLAYS CUTS TO EQUAL WEIGHT FROM OVERWEIGHT
Reuters · 04/11 10:56
U.S. RESEARCH ROUNDUP-Airbnb, Albemarle, Biogen
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Airbnb, Albemarle and Biogen among those with revised targets. AIG, Aflac and Allstate among companies with new targets for the day. Analysts cut target prices on some of the companies.
Reuters · 04/11 07:32
Barclays downgrades Exelixis (EXEL) to a Hold
TipRanks · 04/11 07:05
What Analysts Are Saying About Exelixis Stock
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. The company has an average price target of $26.25 for the next 12 months. In the last three months, 4 analysts have released ratings for Exelix is. The firm's 12-month price target has increased by 7.89% from the previous average of $24.33.
Benzinga · 04/10 17:00
Exelixis Price Target Maintained With a $27.00/Share by JMP Securities
Dow Jones · 04/10 15:19
JMP Securities Reiterates Market Outperform on Exelixis, Maintains $27 Price Target
Benzinga · 04/10 15:08
Buy Rating for Exelixis Amidst Positive Litigation Outlook and Cabozantinib Sales Performance
JMP Securities analyst Silvan Tuerkcan has maintained their bullish stance on Exelixis stock, giving a Buy rating on April 4. The analyst cites the anticipated resolution of intellectual property litigation and solid sales performance of the company's lead product, cabozantinib. RBC Capital has also maintained a buy rating on the stock.
TipRanks · 04/10 04:25
EXEL or REGN: Which Is the Better Value Stock Right Now?
NASDAQ · 04/09 15:40
Analysts Offer Insights on Healthcare Companies: Surrozen (SRZN), Exelixis (EXEL) and Axsome Therapeutics (AXSM)
TipRanks · 04/09 02:10
Weekly Report: what happened at EXEL last week (0401-0405)?
Weekly Report · 04/08 09:01
More
Webull provides a variety of real-time EXEL stock news. You can receive the latest news about Exelixis Inc through multiple platforms. This information may help you make smarter investment decisions.
About EXEL
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.